Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thymosin fraction 5
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular
01
Overview
Thymosin fraction 5 (TF5) is a partially purified bovine thymic extract containing a mixture of biologically active polypeptides, including thymosin alpha-1 and thymosin beta-4. It was one of the first thymic hormone preparations to be extensively studied for its immunomodulatory properties. TF5 works by promoting the differentiation and functional maturation of T-lymphocytes from precursor cells and enhancing various immune functions. In clinical research, it has been explored as an adjuvant therapy for various cancers and primary immunodeficiency diseases. Notably, TF5 has been shown to induce the expression of pyrimidine nucleoside phosphorylase enzymes, such as uridine phosphorylase, which can potentiate the activity of fluoropyrimidine chemotherapy prodrugs like 5'-deoxy-5-fluorouridine by increasing their conversion to active 5-fluorouracil.
- Other names
- Thymosin fraction VThymosin fraction 5
02
Targets
TYMP (Thymidine phosphorylase)UPP1 (Uridine phosphorylase)
Beyond the preview
Go deeper on thymosin fraction 5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thymosin fraction 5.